Navirel (Vinorelbine)

• Vinorelbine is used in the treatment of solid tumours that depend on rapid cell division.
• Non‑small cell lung cancer: improves disease control and overall survival in eligible patients.
• Metastatic breast cancer: provides tumour response and disease stabilization in patients who have received prior therapy.
• Other solid tumours: may be considered in specific protocols where vinorelbine is part of combination regimens.

• Vinorelbine binds to tubulin dimers and prevents their polymerisation into microtubules, disrupting the mitotic spindle. This inhibition arrests cells in the M phase of the cell cycle, leading to apoptosis of rapidly dividing cancer cells while sparing most non‑dividing normal tissues.

Vinorelbine can cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting
• Neutropenia (low white blood cell count)
• Anemia
• Fatigue
• Alopecia (hair loss)
• Constipation

Serious or Rare Side Effects

• Severe neutropenia with febrile infection
• Pulmonary toxicity (interstitial pneumonitis)
• Peripheral neuropathy
• Hypersensitivity reactions including anaphylaxis
• Hypotension during infusion
• Cardiac arrhythmias

• Before initiating therapy, clinicians should assess baseline organ function and monitor patients closely for toxicity.
• Monitor blood counts: perform regular complete blood count to detect neutropenia.
• Assess liver function: adjust dosing if hepatic impairment is present.
• Evaluate pulmonary status: avoid in patients with pre‑existing severe lung disease.
• Use caution with concomitant myelosuppressive agents: increased risk of bone‑marrow suppression.
• Avoid in known hypersensitivity to vinorelbine or other Vinca alkaloids.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can increase vinorelbine exposure.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.
• Concurrent myelosuppressive chemotherapy: heightens risk of severe bone‑marrow toxicity.
• Other Vinca alkaloids: additive neurotoxicity.
• Monoclonal antibodies targeting the same pathway: potential overlapping toxicities.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): monitor coagulation parameters.
• Nephrotoxic agents (e.g., aminoglycosides): watch renal function.
• Drugs causing QT prolongation: observe cardiac rhythm.
• Herbal supplements affecting CYP enzymes (e.g., St John's wort): assess for altered metabolism.